Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37306
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDAUW, Jeroen-
dc.contributor.authorMartens, Pieter-
dc.contributor.authorNIJST, Petra-
dc.contributor.authorMEEKERS, Evelyne-
dc.contributor.authorDEFERM, Sebastien-
dc.contributor.authorGRUWEZ, Henri-
dc.contributor.authorRivero-Ayerza, Maximo-
dc.contributor.authorVan Herendael, Hugo-
dc.contributor.authorPISON, Laurent-
dc.contributor.authorNUYENS, Dieter-
dc.contributor.authorDUPONT, Matthias-
dc.contributor.authorMULLENS, Wilfried-
dc.date.accessioned2022-05-13T15:50:57Z-
dc.date.available2022-05-13T15:50:57Z-
dc.date.issued2022-
dc.date.submitted2022-05-10T14:30:46Z-
dc.identifier.citationEUROPACE, MAR 2022-
dc.identifier.urihttp://hdl.handle.net/1942/37306-
dc.description.abstractAims The aim of this study is to evaluate whether the MADIT-ICD benefit score can predict who benefits most from the addition of implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy (CRT) in real-world patients with heart failure with reduced ejection fraction (HFrEF) and to compare this with selection according to a multidisciplinary expert centre approach. Methods and results Consecutive HFrEF patients who received a CRT for a guideline indication at a tertiary care hospital (Ziekenhuis Oost-Limburg, Genk, Belgium) between October 2008 and September 2016, were retrospectively evaluated. The MADIT-ICD benefit groups (low, intermediate, and high) were compared with the current multidisciplinary expert centre approach. Endpoints were (i) sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and (ii) non-arrhythmic mortality. Of the 475 included patients, 165 (34.7%) were in the lowest, 220 (46.3%) in the intermediate, and 90 (19.0%) in the highest benefit group. After a median follow-up of 34 months, VT/VF occurred in 3 (1.8%) patients in the lowest, 9 (4.1%) in the intermediate, and 13 (14.4%) in the highest benefit group (P < 0.001). Vice versa, non-arrhythmic death occurred in 32 (19.4%) in the lowest, 32 (14.6%) in the intermediate, and 3 (3.3%) in the highest benefit group (P = 0.002). The predictive power for ICD benefit was comparable between expert multidisciplinary judgement and the MADIT-ICD benefit score: Uno's C-statistic 0.69 vs. 0.69 (P = 0.936) for VT/VF and 0.62 vs. 0.60 (P = 0.790) for non-arrhythmic mortality. Conclusion The MADIT-ICD benefit score can identify who benefits most from CRT-D and is comparable with multidisciplinary judgement in a CRT expert centre.-
dc.description.sponsorshipJ.D., E.M., H.G., S.D., and W.M. are researchers for the Limburg Clinical Research Center (LCRC) UHasselt-ZOL-Jessa and supported by the foundation Limburg Sterk Merk (LSM), Province of Limburg, Flemish Government, Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital. H.G. was also supported as predoctoral strategic basic research fellow by the Fund for Scientific Research Flanders (FWO1S83221N).-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS-
dc.subject.otherHeart failure; Implantable cardioverter-defibrillator; Cardiac-
dc.subject.otherresynchronization therapy; Patient selection; MADIT-ICD benefit score-
dc.titleThe MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy-
dc.typeJournal Contribution-
local.format.pages8-
local.bibliographicCitation.jcatA1-
dc.description.notesMullens, W (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.-
dc.description.noteswilfried.mullens@zol.be-
local.publisher.placeGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.statusEarly view-
dc.identifier.doi10.1093/europace/euac039-
dc.identifier.isiWOS:000784737700001-
dc.contributor.orcidGruwez, Henri/0000-0002-9169-265X-
local.provider.typewosris-
local.description.affiliation[Dauw, Jeroen; Martens, Pieter; Nijst, Petra; Meekers, Evelyne; Deferm, Sebastien; Gruwez, Henri; Rivero-Ayerza, Maximo; Van Herendael, Hugo; Pison, Laurent; Nuyens, Dieter; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.-
local.description.affiliation[Dauw, Jeroen; Meekers, Evelyne; Deferm, Sebastien; Gruwez, Henri] UHasselt, LCRC, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium.-
local.description.affiliation[Mullens, Wilfried] UHasselt, Biomed Res Inst, LCRC, Fac Med & Life Sci, Diepenbeek, Belgium.-
local.uhasselt.internationalno-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.fullcitationDAUW, Jeroen; Martens, Pieter; NIJST, Petra; MEEKERS, Evelyne; DEFERM, Sebastien; GRUWEZ, Henri; Rivero-Ayerza, Maximo; Van Herendael, Hugo; PISON, Laurent; NUYENS, Dieter; DUPONT, Matthias & MULLENS, Wilfried (2022) The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy. In: EUROPACE, MAR 2022.-
item.contributorDAUW, Jeroen-
item.contributorMULLENS, Wilfried-
item.contributorDEFERM, Sebastien-
item.contributorMartens, Pieter-
item.contributorDUPONT, Matthias-
item.contributorNUYENS, Dieter-
item.contributorGRUWEZ, Henri-
item.contributorRivero-Ayerza, Maximo-
item.contributorPISON, Laurent-
item.contributorMEEKERS, Evelyne-
item.contributorVan Herendael, Hugo-
item.contributorNIJST, Petra-
crisitem.journal.issn1099-5129-
crisitem.journal.eissn1532-2092-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Jun 29, 2022

Page view(s)

92
checked on Jun 21, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.